These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 19361989)

  • 21. Validation of a computational procedure for the calculation of the polar surface area (PSA) of organic compounds.
    Demopoulos VJ; Anagnostou C; Nicolaou I
    Pharmazie; 2002 Sep; 57(9):652-3. PubMed ID: 12369459
    [No Abstract]   [Full Text] [Related]  

  • 22. The calculation of polar surface area from first principles: an application of quantum chemical topology to drug design.
    Bytheway I; Darley MG; Popelier PL
    ChemMedChem; 2008 Mar; 3(3):445-53. PubMed ID: 18161739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity.
    Young RJ; Green DV; Luscombe CN; Hill AP
    Drug Discov Today; 2011 Sep; 16(17-18):822-30. PubMed ID: 21704184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Increasing the solubility and permeability of pharmacons with pharmaceutical technological methods].
    Aigner Z
    Acta Pharm Hung; 2008; 78(1):3-10. PubMed ID: 18476363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shapes of membrane permeability-lipophilicity curves: extension of theoretical models with an aqueous pore pathway.
    Camenisch G; Folkers G; van de Waterbeemd H
    Eur J Pharm Sci; 1998 Oct; 6(4):325-29. PubMed ID: 9795090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Ahlin G; Karlsson J; Pedersen JM; Gustavsson L; Larsson R; Matsson P; Norinder U; Bergström CA; Artursson P
    J Med Chem; 2008 Oct; 51(19):5932-42. PubMed ID: 18788725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Permeability diagnosis model in drug discovery: a diagnostic tool to identify the most influencing properties for gastrointestinal permeability.
    Wang J; Skolnik S
    Curr Top Med Chem; 2013; 13(11):1308-16. PubMed ID: 23675937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beyond size, ionization state, and lipophilicity: influence of molecular topology on absorption, distribution, metabolism, excretion, and toxicity for druglike compounds.
    Yang Y; Engkvist O; Llinàs A; Chen H
    J Med Chem; 2012 Apr; 55(8):3667-77. PubMed ID: 22443161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On quantitative relationships between drug-like compound lipophilicity and plasma free fraction in monkey and human.
    Zoghbi SS; Anderson KB; Jenko KJ; Luckenbaugh DA; Innis RB; Pike VW
    J Pharm Sci; 2012 Mar; 101(3):1028-39. PubMed ID: 22170327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A modified fast (4 day) 96-well plate Caco-2 permeability assay.
    Uchida M; Fukazawa T; Yamazaki Y; Hashimoto H; Miyamoto Y
    J Pharmacol Toxicol Methods; 2009; 59(1):39-43. PubMed ID: 19049886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular topology analysis of the differences between drugs, clinical candidate compounds, and bioactive molecules.
    Chen H; Yang Y; Engkvist O
    J Chem Inf Model; 2010 Dec; 50(12):2141-50. PubMed ID: 21077637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of some factors contributing to negative food effects.
    Marasanapalle VP; Crison JR; Ma J; Li X; Jasti BR
    Biopharm Drug Dispos; 2009 Mar; 30(2):71-80. PubMed ID: 19226652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Escape from flatland: increasing saturation as an approach to improving clinical success.
    Lovering F; Bikker J; Humblet C
    J Med Chem; 2009 Nov; 52(21):6752-6. PubMed ID: 19827778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coumarins permeability in Caco-2 cell model.
    Galkin A; Fallarero A; Vuorela PM
    J Pharm Pharmacol; 2009 Feb; 61(2):177-84. PubMed ID: 19178764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of corneal permeability using polar molecular surface areas.
    Fu XC; Liang WQ
    Pharmazie; 2001 Aug; 56(8):667. PubMed ID: 11534350
    [No Abstract]   [Full Text] [Related]  

  • 36. Dependence of molecular properties on proteomic family for marketed oral drugs.
    Vieth M; Sutherland JJ
    J Med Chem; 2006 Jun; 49(12):3451-3. PubMed ID: 16759087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipophilicity in drug discovery.
    Waring MJ
    Expert Opin Drug Discov; 2010 Mar; 5(3):235-48. PubMed ID: 22823020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of additive/nonadditive effects in structure-activity relationships: implications for iterative drug design.
    Patel Y; Gillet VJ; Howe T; Pastor J; Oyarzabal J; Willett P
    J Med Chem; 2008 Dec; 51(23):7552-62. PubMed ID: 19012393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality guidelines for oral drug candidates: dose, solubility and lipophilicity.
    Bayliss MK; Butler J; Feldman PL; Green DV; Leeson PD; Palovich MR; Taylor AJ
    Drug Discov Today; 2016 Oct; 21(10):1719-1727. PubMed ID: 27423371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The constituents of Cibotium barometz and their permeability in the human Caco-2 monolayer cell model.
    Wu Q; Yang XW
    J Ethnopharmacol; 2009 Sep; 125(3):417-22. PubMed ID: 19635547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.